News

2 Beaten-Down Dividend Growth Stocks to Buy on the Dip
It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...
Obesity lab: India becomes ground zero for weight-loss drug race
India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...
Eli Lilly: Competition Melts Away
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
Should You Invest in This Under-the-Radar Weight Loss Stock?
Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...
Many US employers plan to pare health benefits as weight-loss spending soars
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
Zacks Investment Research on MSN4d
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
New Scientist5d
You don't need to take drugs like Ozempic consistently to lose weight
People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...